Smith & Nephew Stock Rating Lowered by Goldman Sachs Group Inc. (SN)
Smith & Nephew (LON:SN) was downgraded by analysts at Goldman Sachs Group Inc. to a “sell” rating in a research report issued to clients and investors on Wednesday, Analyst Ratings Network.com reports. They currently have a GBX 720 ($11.82) price objective on the stock, down from their previous price objective of GBX 780 ($12.80). Goldman Sachs Group Inc.’s target price would indicate a potential downside of 18.14% from the stock’s previous close.
A number of other analysts have also recently weighed in on SN. Analysts at Citigroup Inc. raised their price target on shares of Smith & Nephew from GBX 830 ($13.62) to GBX 870 ($14.28) in a research note to investors on Monday. They now have a “neutral” rating on the stock. Separately, analysts at Jefferies Group raised their price target on shares of Smith & Nephew from GBX 900 ($14.77) to GBX 1,000 ($16.41) in a research note to investors on Tuesday, January 14th. They now have a “buy” rating on the stock. Finally, analysts at Sanford C. Bernstein reiterated an “outperform” rating on shares of Smith & Nephew in a research note to investors on Friday, January 10th. They now have a GBX 950 ($15.59) price target on the stock. Three investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and five have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of GBX 809.24 ($13.28).
Smith & Nephew (LON:SN) opened at 886.50 on Wednesday. Smith & Nephew has a one year low of GBX 692.592 and a one year high of GBX 884.00. The stock’s 50-day moving average is GBX 856.5 and its 200-day moving average is GBX 803.1. The company’s market cap is £7.970 billion.
Smith & Nephew plc is a global medical devices business operating in the markets for orthopaedic reconstruction and trauma, endoscopy (LON:SN) and advanced wound management.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.